4,5-Dihydro-5-(3-hydroxyphenyl)-2-(thien-2-yl)-1,3-oxazole | 112636-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4,5-Dihydro-5-(3-hydroxyphenyl)-2-(thien-2-yl)-1,3-oxazole
• 英文别名: 4,5-Dihydro-5-(3-hydroxyphenyl)-2-(2-thienyl)-1,3-oxazole；3-(2-thiophen-2-yl-4,5-dihydro-1,3-oxazol-5-yl)phenol
• CAS: 112636-21-2
• 化学式: C₁₃H₁₁NO₂S
• 分子量: 245.302
• InChiKey: NFGLSIJOCDPRLG-UHFFFAOYSA-N

物化性质

• 沸点：
  444.0±45.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,5-Dihydro-5-(3-hydroxyphenyl)-2-(thien-2-yl)-1,3-oxazole 在 盐酸 、 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 21.0h， 生成 N-[2-hydroxy-2-[3-(2-quinolinylmethoxy)phenyl]ethyl]-2-thiophene carboxamide
  参考文献：
  名称：

  Phenylephrine derivatives as leukotriene D4 antagonists

  摘要：

  Two series of phenylephrine derivatives were prepared and tested as inhibitors of leukotriene D4 (LTD4) induced and ovalbumin-induced bronchospasm in the guinea pig. The most potent compound of the urea series, (R)-N,N-diethyl-N-[2-hydroxy-2-[3-(2-quinolinylmethoxy)phenyl]ethyl]-N- methylurea (3, Wy-47,120), was orally active with ED50's of 56 mg/kg vs. LTD4 and 55 mg/kg vs. ovalbumin. When tested as an antagonist of LTD4-induced contraction of isolated guinea pig tracheal strips, 3 was a competitive inhibitor with a p kappa B value of 5.22. In the second series, (R)-3-methyl-5-[3-(2-quinolinylmethoxy)phenyl]-2-oxazolidinone (26, Wy-47,674) had oral ED50's of 36 mg/kg against LTD4 and 95 mg/kg against ovalbumin. Compound 26 selectively antagonized contractile responses of guinea pig trachea evoked by LTD4 (p kappa B = 6.09). In the cat coronary artery, 3 dilated the preparation and blocked the coronary constrictor effect of LTD4. Compound 3 (0.13 mg/kg, iv) also preserved myocardial integrity in rats 48 h after coronary artery ligation. When tested in the rat alcohol-induced gastric lesion model, 3 and 26 manifested a dose-dependent mucosal protection against ethanol.

  DOI：

  10.1021/jm00394a026
• 作为产物：
  描述：

  methyl thiophene-2-carboximidate 、 盐酸去甲苯福林 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 4,5-Dihydro-5-(3-hydroxyphenyl)-2-(thien-2-yl)-1,3-oxazole
  参考文献：
  名称：

  Phenylephrine derivatives as leukotriene D4 antagonists

  摘要：

  Two series of phenylephrine derivatives were prepared and tested as inhibitors of leukotriene D4 (LTD4) induced and ovalbumin-induced bronchospasm in the guinea pig. The most potent compound of the urea series, (R)-N,N-diethyl-N-[2-hydroxy-2-[3-(2-quinolinylmethoxy)phenyl]ethyl]-N- methylurea (3, Wy-47,120), was orally active with ED50's of 56 mg/kg vs. LTD4 and 55 mg/kg vs. ovalbumin. When tested as an antagonist of LTD4-induced contraction of isolated guinea pig tracheal strips, 3 was a competitive inhibitor with a p kappa B value of 5.22. In the second series, (R)-3-methyl-5-[3-(2-quinolinylmethoxy)phenyl]-2-oxazolidinone (26, Wy-47,674) had oral ED50's of 36 mg/kg against LTD4 and 95 mg/kg against ovalbumin. Compound 26 selectively antagonized contractile responses of guinea pig trachea evoked by LTD4 (p kappa B = 6.09). In the cat coronary artery, 3 dilated the preparation and blocked the coronary constrictor effect of LTD4. Compound 3 (0.13 mg/kg, iv) also preserved myocardial integrity in rats 48 h after coronary artery ligation. When tested in the rat alcohol-induced gastric lesion model, 3 and 26 manifested a dose-dependent mucosal protection against ethanol.

  DOI：

  10.1021/jm00394a026

文献信息

• 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
  申请人：American Home Products Corporation

  公开号：US04681940A1

  公开（公告）日：1987-07-21

  There are disclosed compounds of the formula ##STR1## wherein X is N or CR.sup.2 Y is O, S, NR.sup.2, CHR.sup.2 or C(R.sup.2).sub.2 when n=0, or N or CR.sup.2 when n=1; p is 0-3; R.sup.1 is ##STR2## R.sup.2 is hydrogen or lower alkyl; R.sup.3 is hydrogen, lower alkyl, phenyl, thienyl, furyl, pyridyl, ##STR3## --C(R.sup.4).sub.3 or --(CH.sub.2).sub.p COOR.sup.2 ; R.sup.4 is halo; Z is O or S; and the pharmaceutically acceptable salts thereof, and their use in the treatment of luekotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

  公开了以下式子的化合物：##STR1## 其中X为N或CR.sup.2，Y为O、S、NR.sup.2、CHR.sup.2或C(R.sup.2).sub.2当n=0时，或N或CR.sup.2当n=1时；p为0-3；R.sup.1为##STR2## R.sup.2为氢或较低的烷基；R.sup.3为氢、较低的烷基、苯基、噻吩基、呋喃基、吡啶基、##STR3## --C(R.sup.4).sub.3或--(CH.sub.2).sub.p COOR.sup.2；R.sup.4为卤素；Z为O或S；以及其药学上可以接受的盐，以及它们在治疗白三烯介导的鼻-支气管阻塞性通气道疾病中的用途，例如过敏性鼻炎、过敏性支气管哮喘等，在银屑病、溃疡性结肠炎、类风湿性关节炎以及其他即时超敏反应中的用途。
• 5-Phenyl-2-oxazole derivatives as anti-inflammatory/antiallergic agents
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0226342A1

  公开（公告）日：1987-06-24

  There are disclosed compounds of formula wherein X is N or CR2; Y is O, S, NR2, CHR2 or C(R2)2 when n = 0 or N or CR2 when n is 1; p is 0 to 3, providing that when p is 0, X is N; R' is R2 is hydrogen or lower alkyl; R3 is hydrogen, lower alkyl, phenyl, thienyl, furyl, pyridyl, C(R4)3 or -(CH2)gCOOR2; R4 is halo; X is 0 or S and q is 0 to 3; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

  公开了如下式子的化合物 其中 X 是 N 或 CR2； 当 n = 0 时，Y 是 O、S、NR2、CHR2 或 C(R2)2；当 n 为 1 时，Y 是 N 或 CR2； p 为 0 至 3，当 p 为 0 时，X 为 N； R' 是 R2 是氢或低级烷基 R3 是氢、低级烷基、苯基、噻吩基、呋喃基、吡啶基、 C(R4)3或-(CH2)gCOOR2； R4 是卤代；X 是 0 或 S，q 是 0 至 3； 及其药学上可接受的盐，以及它们在治疗白三烯介导的鼻-支气管阻塞性气道疾病（如过敏性鼻炎、过敏性支气管哮喘等）、银屑病、溃疡性结肠炎、类风湿性关节炎以及其他即时超敏反应中的用途。
• MUSSER, JOHN H.;BENDER, REINHOLD H. W.
  作者：MUSSER, JOHN H.、BENDER, REINHOLD H. W.

  DOI：——

  日期：——
• US4681940A
  申请人：——

  公开号：US4681940A

  公开（公告）日：1987-07-21